Scinai Immunotherapeutics Ltd. Announces The Publication Following Peer-Review Of An Article Titled "Nanobodies To Multiple Spike Variants And Inhalation Of Nanobody-Containing Aerosols Neutralize SARS-coV-2 In Cell Culture And Hamsters"
Portfolio Pulse from Benzinga Newsdesk
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) has announced the peer-reviewed publication of an article in Antiviral Research, showcasing the potential of their aerosolized NanoAbs for treating coronavirus infections. The NanoAbs, developed in collaboration with MPI-NAT and UMG, have shown promising results in neutralizing SARS-CoV-2 in cell culture and hamsters. The company is actively seeking partnerships for their COVID-19 project and is also progressing with an anti-IL-17 NanoAb for autoimmune diseases. Scinai's CDMO unit has garnered customer interest and received a grant from the Israeli Innovation Authority.
December 11, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scinai Immunotherapeutics Ltd. has published promising research on NanoAbs for COVID-19, is seeking partnerships, and is advancing in autoimmune disease treatment, which may positively impact investor sentiment.
The publication of positive peer-reviewed research typically has a favorable impact on a biotech company's stock price, as it validates the company's R&D efforts and potential for successful product development. The active search for partnerships and progress in the pipeline can also be seen as positive indicators for future revenue streams and growth potential. The recent financial support from the Israeli Innovation Authority further adds credibility to the company's operations.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100